









































































































































































































































































?????Inflammatory processes and bone metabolism??????????
? ??Willy Hofstetter???????????????????????
?????
It has become increasingly evident that the immune system and bone are forming a close anatomi-
cal and functional relationship. Inflammatory processes are found to profoundly affect bone metabo-
lism by creating a local environment favoring osteoclastogenesis and bone resorption. A limited set
of cytokines, including interleukin-1 (IL1) and tumor necrosis factor alpha (TNFα), as well as IL6 or
IL17 are released by immune cells upon activation in diseases and surgical complications such as
Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), osteoporosis or loosening of permanent im-
plants. We have focused on the role of TNFα in bone metabolism and we found that the cytokine, de-
pending on the target cell populations, can exert pro- as well as anti-osteoclastogenic effects.
A feature in inflammatory joint diseases like RA and AS is the development of osteolytic lesions in
the subchondral bone. In contrast to earlier days, when the use of anti-inflammatory steroids was
the major therapy, more sophisticated biological drugs, such as antibodies against TNFα or IL6 re-
ceptor antagonists, are available today. To investigate the mechanisms of action of TNFα in RA and
AS patients that were subjected to a therapeutic protocol with inactivating anti-TNFα antibodies,
peripheral blood mononuclear cells (PBMC) were isolated at pre-determined time points. The cells
were culture on dentin slices in media containing macrophage-colony stimulating factor (MCSF) and
receptor activator of NF-κB ligand (RANKL) and the resorptive activity of the cells was determined.
The ability of the cells to develop into bone resorbing osteoclasts was greatly reduced within days af-
ter the onset of the therapeutic protocol. Further studies revealed changes in the cellular composi-
tion within PBMC of the patients that may at least partially account for the observed reduction in
???? ?? ???????
bone resorption in vitro.
Even though TNFα has been been described as a potent mediator of bone loss by inducing resorp-
tion, while inhibiting formation, the actions of the cytokine may be more complex. When added to a
co-culture of primary murine osteoblasts with osteoclast progenitor cells (OPC), TNFα was found to
inhibit the development of osteoclast in dependence of its dose. Two effects were found to overlay
each other, a stimulation of osteoclastogenesis through a direct action on OPC and an inhibition of
the process via osteoblast lineage cells. Expression analysis, which was complemented by experi-
mental evidence, suggested that the haematopoietic growth factor granulocyte-macrophage colony
stimulating factor (GMCSF), which is known to inhibit osteoclastogenesis, was released upon treat-
ment of osteoblast lineage cells with TNF.
The TNFα-induced release of GMCSF was attenuated by anti-inflammatory compounds , and
thereby, development of osteoclasts was restored.
Thus, TNFα can be described as a growth factor that exerts opposite effects on developing osteo-
clast lineage cells . Through a direct action on these cells , in the presence of limiting levels of
RANKL, TNFα potently stimulates development and activity of osteoclasts. Indirectly, through the
release of GMCSF, however, TNFα profoundly inhibits osteoclastogenesis by blocking RANK expres-
sion and rendering the cells unresponsive to RANKL. Combining the in vivo and in vitro data, a
model is postulated in which GMCSF acts on osteoclast lineage cells in separate physiological com-
partments. In circulation, the growth factor may act as a proliferation factor for monocyte lineage
cells, increasing the pool of potential osteoclast progenitors. Upon migration to the bone marrow, the
progenitors are exposed to a local osteoclastogenic environment that directs osteoclastic differentia-






















































??????????RANKL?receptor activator for Nuclear Factor kappa B ligand/osteoclast dif-
ferentiation factor : ODF???????????
RANKL?????????????????????????????????? RANKL??




















????????? bFGF?????????????Yanagisawa−Miwa et al. Science??????VEGF
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?????Periodontal treatment : model for integrated care???????????????












?????A new strategy for accelerating wound healing and tissue regeneration
? ??Henry C. Y. Su?Biomedical Research Unit, School of Dentistry National Yang−Ming
University, Taipei, Taiwan?
?????
There is growing clinical interest in regenerative medicine in the use of biomaterials made from
autologous human blood because these products are biodegradable, do not induce tissue reaction,
and exhibit valuable physiological functions. Blood−derived biomaterials obtained by combining a
platelet−rich plasma (PRP) with thrombin are called platelet gels (PLT gels). The mixing of both
fractions results in (a) the conversion of fibrinogen into fibrin, (b) the activation of platelets and (c)
the release of a myriad of growth factors (GF) stored in the α−granules. Upon activation by agonists,
platelets release a myriad of functional molecules which play a key role in tissue repair and regen-
eration by stimulation and differentiation of local stem cells. Among those are the numerous growth
factors : platelet−derived growth factors (PDGF) −AA, −BB, or −AB, transforming growth factor−β
(TGF−β 1 and −2), vascular endothelium growth factor (VEGF), epidermal growth factor (EGF), fi-
broblast growth factor−1 (FGF−1), etc. PLT gels are now explored and proven to be unique non−
toxic biocompatible tools for tissue engineering and cell therapies. In this presentation, a new strat-
egy to optimize post−operative wound healing using blood−derived GF−rich biomaterials will be



































































?????Timing of guided bone regeneration and 3 D guided implant
?GBR???????D guided??????????
? ??? ???Philip Lu??Assistant Professor, Baylor College of Dentistry, Texas A &M
University System?
?????
Knowledge of the potential and limitation of guided bone regeneration in the dental implant ther-
apy is essential for the achievement of predictable outcomes. The understanding of the significance
of the timing of tooth extraction relative to the use of guided bone regeneration and dental implant
placement can enhance the success of dental implants. The advantages and disadvantages for the
use of guided bone regeneration in immediate, recent, delayed and mature sites will be discussed.
This presentation will provide evidence on the effectiveness of guided bone regeneration using bone
grafts and resorbable membranes. Additionally, a new precise treatment strategy called “3 D guided
implant”, invented by Dr. Lu, which can avoid the incorrect angulations for dental implant place-
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